Texas Oncology
Welcome,         Profile    Billing    Logout  
 59 Trials 
113 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gadgeel, Shirish M
NCT01665443: Bevacizumab and Docetaxel in Treating Older Patients With Stage III-IV Non-Small Cell Lung Cancer

Active, not recruiting
2
8
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, docetaxel, RP 56976, Taxotere, TXT
Barbara Ann Karmanos Cancer Institute, Genentech
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
12/14
 
NCT02642042: Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
2
60
US
Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
KRAS Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/19
03/25
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Checkmark Trial initiated for LGSOC and KRAS mutated NSCLC
Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC
Completed
2
90
Europe, US
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation
08/23
12/23
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
CA239-0010, NCT05609578: Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Recruiting
2
90
Europe, US, RoW
Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
Mirati Therapeutics Inc.
Advanced NSCLC, Metastatic Lung Cancer
06/26
12/26
LUNG-MAP SUB-STUDY, NCT06116682: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Recruiting
2
88
US
Amivantamab, Amivantamab-vmjw, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, CNTO-4424, JNJ 61186372, JNJ-611, JNJ-61186372, JNJ61186372, Rybrevant, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma
05/28
05/28
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
NCT04442126 / 2021-000441-41: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Terminated
1/2
52
Europe, US, RoW
NM21-1480
Numab Therapeutics AG
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
02/24
02/24
NCT05023486: NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

Recruiting
1/2
140
US
NP-G2-044 Monotherapy, Anti-PD-1 Therapy, NP-G2-044 Combination therapy
Novita Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumor Malignancies
09/25
09/25
(MARGARET), NCT04683250: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Recruiting
1/2
202
Japan, US
TAS0953/HM06
Helsinn Healthcare SA, ICON Clinical Research
RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
03/25
09/25
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT04982224: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Recruiting
1/2
237
US
REGN5093-M114, Cemiplimab
Regeneron Pharmaceuticals
Advanced NSCLC
02/30
02/30
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SHIELD-1, NCT03993873: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Active, not recruiting
1
95
Europe, US, RoW
elzovantinib (TPX-0022)
Turning Point Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
01/24
03/26
HEROEX-1, NCT06521554: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC

Recruiting
1
120
US
NVL-330
Nuvalent Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
03/26
03/26
NCT06607185: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Recruiting
1
750
Europe, Japan, US, RoW
LY4066434., Cetuximab, Nab paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, 5Fluorouracil, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Eli Lilly and Company
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
01/30
01/30
PATHFINDER 2, NCT05155605: a Multi-Cancer Early Detection Study

Active, not recruiting
N/A
35885
Canada, US
Multi-Cancer Early Detection Test
GRAIL, Inc.
Early Detection of Cancer, Cancer
02/26
04/28
Owens, Michelle Y
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
ZN-c3-004, NCT04814108: A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
76
Canada, US, RoW
ZN-c3, azenosertib, KP-2638
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Uterine Serous Carcinoma
11/24
05/25
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
ENGOT-ov60, NCT04625270 / 2020-004264-26: A Study of Avutometinib (VS-6766) V. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer with and Without a KRAS Mutation

Active, not recruiting
2
225
Europe, Canada, US
avutometinib (VS-6766), avutometinib (VS-6766) and defactinib, avutometinib (VS-6766) and VS-6063
Verastem, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
11/24
12/26
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
05/25
NCT01851642: Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Recruiting
N/A
220
US
History and physical exam., H&P, Blood draw., Phlebotomy, Pulmonary function testing., PFTs, Albuterol inhaler., Ventolin, Proventil, Proventil-HFA, AccuNeb, Vospire, ProAir
University of Florida
Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
07/32
07/33
NCT00500123: The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

Recruiting
N/A
50000
US
Alpha-1 Antitrypsin Genotype
University of Florida
Alpha-1 Antitrypsin Deficiency
01/50
01/50
Brenner, Andrew
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03032484: TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Completed
2
25
US
Bevacizumab, Avastin, TVB-2640
The University of Texas Health Science Center at San Antonio
Astrocytoma
04/20
04/21
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04559230: Sacituzumab Govitecan in Recurrent Glioblastoma

Recruiting
2
40
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio
Glioblastoma
02/26
08/26
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
ReSPECT-GBM, NCT01906385: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Recruiting
1/2
55
US
Rhenium Liposome Treatment, Rhenium-186 NanoLiposome
Plus Therapeutics, National Cancer Institute (NCI)
Glioma
01/25
01/25
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT02538484: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

Completed
1
24
US
Letrozole, Femara, Fish Oil, Omega-3
The University of Texas Health Science Center at San Antonio
Breast Cancer
03/20
03/20
NCT03995706: Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0

Completed
1
26
US
Sacituzumab Govitecan
The University of Texas Health Science Center at San Antonio, Gilead Sciences
Glioblastoma
06/22
03/24
NCT05460507: Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Not yet recruiting
1
40
NA
Retreatment Rhenium Liposome, Rhenium-186 NanoLiposome
Plus Therapeutics
Glioma
03/28
03/28
ReSPECT-LM, NCT05034497: Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Recruiting
1
18
US
186RNL, Rhenium-186 NanoLiposome
Plus Therapeutics
Leptomeningeal Metastasis
12/25
06/26
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
05/25
05/27
Bridges, Benjamin B
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
Hrom, John
NCT05434663: Safety Study of Repeat Doses of SUSTOL in Adults

Active, not recruiting
4
300
US
SUSTOL, Granisetron extended-release injection for subcutaneous use
Heron Therapeutics
Chemotherapy-Induced Nausea and Vomiting (CINV)
10/25
10/25
NCT05199818: Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Recruiting
3
328
US
Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
Xiamen LP Pharmaceutical Co., Ltd
Chemotherapy-induced Nausea and Vomiting
09/23
11/23
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
Melear, Jason
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
ASC4START, NCT05456191: A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

Active, not recruiting
3
571
Europe, Canada, US, RoW
Asciminib, ABL001, Nilotinib
Novartis Pharmaceuticals
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
03/25
07/31
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
ALPHA3, NCT06500273: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
2
250
US
cemacabtagene ansegedleucel, cema-cel, ALLO-647, Fludarabine, Fludara®, Cyclophosphamide, Cytoxan®, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, Foresight Lymphoma MRD Therapy Selection Test
Allogene Therapeutics, Foresight Diagnostics, Inc.
Large B-cell Lymphoma
08/27
08/31
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
73
US
Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid
US Oncology Research, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
05/26
05/26
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Active, not recruiting
1
160
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
12/24
05/25
QUILT-3.100, NCT05976828: IBRX-042 in Participants with HPV-Associated Tumors

Recruiting
1
12
US
IBRX-042, IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine)
ImmunityBio, Inc.
HPV-Related Carcinoma
09/25
08/33
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
SGNBCMA-001, NCT03582033: A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Terminated
1
83
US
SEA-BCMA, dexamethasone, pomalidomide
Seagen Inc.
Multiple Myeloma
11/23
11/23
Uyeki, James
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Recruiting
2
142
US
Olvimulogene nanivacirepvec, Olvi-Vec, GL-ONC, GLV-1h68, Platinum chemotherapy: carboplatin or cisplatin, Brand of drug is based on institutional procurement, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Genelux Corporation, Newsoara Biopharma Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
02/27
07/29
Teneriello, Michael
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
06/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed
2
150
US, RoW
Paclitaxel, Afuresertib, LAE002
Laekna Limited
Platinum-resistant Ovarian Cancer
07/23
06/24
Patt, Debra A
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
Kingsley, Edwin
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
Vaillant, Brian
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
BPM31510IV-11, NCT04752813: A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)

Recruiting
2
50
US
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
BPGbio, BPGbio
Glioblastoma, Glioblastoma Multiforme
02/25
12/25
Cline, Vivian J
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark Elderly chemo-intolerant Hodgkin's lymphoma patients
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Terminated
2
177
Europe, Canada, US
Drug GC4711, Placebo
Galera Therapeutics, Inc.
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
11/23
11/23
Jerome, Mary S
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting
1
499
US
TAB004, JS004, Toripalimab, TAB001, JS001
TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
03/26
03/26
Crow
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
Elmore, Kevin
BPM31510IV-11, NCT04752813: A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)

Recruiting
2
50
US
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
BPGbio, BPGbio
Glioblastoma, Glioblastoma Multiforme
02/25
12/25
Hutton, Colleen
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
Yorio, Jeffrey
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
McCallister, Angelica
POD1UM-303, NCT04472429 / 2020-000826-24: Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (/InterAACT 2).

Hourglass Dec 2024 - Dec 2024 : sBLA submission for SCAC
Active, not recruiting
3
308
Europe, Japan, US, RoW
carboplatin, paclitaxel, retifanlimab, INCMGA00012
Incyte Corporation
Squamous Cell Carcinoma of the Anal Canal
04/24
03/26
 

Download Options